Synthesis, Biological Evaluation, and Molecular Docking of Ugi Products Containing a Zinc-Chelating Moiety as Novel Inhibitors of Histone Deacetylases
- 3 April 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (9) , 2776-2785
Abstract
HDAC inhibitors show great promise for the treatment of cancer. As part of a broader effort to explore the SAR of HDAC inhibitors, synthesis, biological evaluation, and molecular docking of novel Ugi products containing a zinc-chelating moiety are presented. One compound shows improved inhibitory potencies compared to SAHA, demonstrating that hindered lipophilic residues grafted on the peptide scaffold of the α-aminoacylamides can be favorable in the interaction with the enzyme.Keywords
This publication has 21 references indexed in Scilit:
- Histone Deacetylase Inhibitors: From Bench to ClinicJournal of Medicinal Chemistry, 2008
- EXPRESSION OF CONCERN: Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cellsBritish Journal of Pharmacology, 2008
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006
- Histone Deacetylase InhibitorsJournal of Medicinal Chemistry, 2003
- Histone deacetylase as a new target for cancer chemotherapyCancer Chemotherapy and Pharmacology, 2001
- Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxinProceedings of the National Academy of Sciences, 2000
- Multicomponent Reactions with Isocyanides2000
- Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitorsNature, 1999